Aydin Huseynov
Stock Analyst at Ladenburg Thalmann
(0.70)
# 4,114
Out of 5,130 analysts
57
Total ratings
32%
Success rate
-27.04%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Aydin Huseynov
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AKTX Akari Therapeutics, | Initiates: Buy | $1 | $0.28 | +254.99% | 1 | Jan 5, 2026 | |
| ARDX Ardelyx | Assumes: Buy | $11 | $7.74 | +42.12% | 1 | Mar 7, 2025 | |
| URGN UroGen Pharma | Assumes: Buy | $31 | $21.25 | +45.88% | 1 | Feb 19, 2025 | |
| MRKR Marker Therapeutics | Maintains: Buy | $11 → $19 | $2.00 | +850.00% | 2 | Oct 21, 2024 | |
| CRVS Corvus Pharmaceuticals | Maintains: Buy | $12 → $21 | $6.79 | +209.28% | 3 | Sep 16, 2024 | |
| CMPX Compass Therapeutics | Upgrades: Buy | $5 | $5.35 | -6.54% | 2 | Sep 16, 2024 | |
| ACRV Acrivon Therapeutics | Upgrades: Buy | $16 | $1.75 | +814.29% | 3 | Sep 16, 2024 | |
| CLDI Calidi Biotherapeutics | Initiates: Buy | $120 | $1.15 | +10,334.78% | 1 | Jun 27, 2024 | |
| CAPR Capricor Therapeutics | Maintains: Buy | $24 → $25 | $23.84 | +4.87% | 2 | May 14, 2024 | |
| SPRB Spruce Biosciences | Downgrades: Neutral | n/a | $79.99 | - | 3 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $2,000 | $2.35 | +85,006.38% | 1 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $1.18 | +493.22% | 1 | Dec 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $5.12 | +95.31% | 1 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $14.26 | +320.76% | 1 | Sep 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $6 | $1.41 | +325.53% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $3.52 | +184.09% | 3 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $375 → $240 | $1.99 | +11,960.30% | 2 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $104 → $182 | $2.89 | +6,197.58% | 2 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Speculative Buy | $4,500 → $2,000 | $3.36 | +59,423.81% | 1 | Apr 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $13.37 | - | 4 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.17 | - | 2 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $1.14 | +426.32% | 1 | Jul 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $8.46 | +148.23% | 1 | Jul 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10,500 | $12.21 | +85,895.09% | 1 | May 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $3.67 | +908.17% | 1 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $300 | $39.71 | +655.48% | 3 | Nov 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $796.55 | - | 6 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $89 | $106.87 | -16.72% | 2 | Jul 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | n/a | $135.79 | - | 1 | Sep 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $336 | $1.56 | +21,438.46% | 1 | May 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $4.02 | +347.76% | 1 | Mar 19, 2020 |
Akari Therapeutics,
Jan 5, 2026
Initiates: Buy
Price Target: $1
Current: $0.28
Upside: +254.99%
Ardelyx
Mar 7, 2025
Assumes: Buy
Price Target: $11
Current: $7.74
Upside: +42.12%
UroGen Pharma
Feb 19, 2025
Assumes: Buy
Price Target: $31
Current: $21.25
Upside: +45.88%
Marker Therapeutics
Oct 21, 2024
Maintains: Buy
Price Target: $11 → $19
Current: $2.00
Upside: +850.00%
Corvus Pharmaceuticals
Sep 16, 2024
Maintains: Buy
Price Target: $12 → $21
Current: $6.79
Upside: +209.28%
Compass Therapeutics
Sep 16, 2024
Upgrades: Buy
Price Target: $5
Current: $5.35
Upside: -6.54%
Acrivon Therapeutics
Sep 16, 2024
Upgrades: Buy
Price Target: $16
Current: $1.75
Upside: +814.29%
Calidi Biotherapeutics
Jun 27, 2024
Initiates: Buy
Price Target: $120
Current: $1.15
Upside: +10,334.78%
Capricor Therapeutics
May 14, 2024
Maintains: Buy
Price Target: $24 → $25
Current: $23.84
Upside: +4.87%
Spruce Biosciences
Mar 14, 2024
Downgrades: Neutral
Price Target: n/a
Current: $79.99
Upside: -
Feb 8, 2024
Initiates: Buy
Price Target: $2,000
Current: $2.35
Upside: +85,006.38%
Dec 27, 2023
Initiates: Buy
Price Target: $7
Current: $1.18
Upside: +493.22%
Oct 10, 2023
Initiates: Buy
Price Target: $10
Current: $5.12
Upside: +95.31%
Sep 22, 2023
Initiates: Buy
Price Target: $60
Current: $14.26
Upside: +320.76%
Aug 14, 2023
Maintains: Buy
Price Target: $10 → $6
Current: $1.41
Upside: +325.53%
Jun 5, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $3.52
Upside: +184.09%
May 16, 2023
Maintains: Buy
Price Target: $375 → $240
Current: $1.99
Upside: +11,960.30%
Apr 28, 2023
Maintains: Buy
Price Target: $104 → $182
Current: $2.89
Upside: +6,197.58%
Apr 4, 2023
Maintains: Speculative Buy
Price Target: $4,500 → $2,000
Current: $3.36
Upside: +59,423.81%
Nov 4, 2022
Downgrades: Neutral
Price Target: n/a
Current: $13.37
Upside: -
Aug 23, 2022
Downgrades: Neutral
Price Target: n/a
Current: $1.17
Upside: -
Jul 27, 2022
Initiates: Buy
Price Target: $6
Current: $1.14
Upside: +426.32%
Jul 13, 2022
Initiates: Buy
Price Target: $21
Current: $8.46
Upside: +148.23%
May 6, 2022
Initiates: Buy
Price Target: $10,500
Current: $12.21
Upside: +85,895.09%
May 2, 2022
Initiates: Buy
Price Target: $37
Current: $3.67
Upside: +908.17%
Nov 8, 2021
Upgrades: Buy
Price Target: $300
Current: $39.71
Upside: +655.48%
Nov 5, 2021
Downgrades: Hold
Price Target: n/a
Current: $796.55
Upside: -
Jul 20, 2021
Upgrades: Buy
Price Target: $89
Current: $106.87
Upside: -16.72%
Sep 30, 2020
Initiates: Hold
Price Target: n/a
Current: $135.79
Upside: -
May 21, 2020
Initiates: Buy
Price Target: $336
Current: $1.56
Upside: +21,438.46%
Mar 19, 2020
Initiates: Buy
Price Target: $18
Current: $4.02
Upside: +347.76%